Statin Use in Metabolic Dysfunction-Associated Steatotic Liver Disease and Effects on Vibration-Controlled Transient Elastography-Derived Scores—A Population-Based Inverse Probability Treatment Weighting Analysis
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease globally. The impact of statins on liver fibrosis severity in MASLD individuals remains uncertain, despite their known cardiovascular benefits. Methods: A cross-secti...
Saved in:
| Main Authors: | Natchaya Polpichai, Sakditad Saowapa, Aunchalee Jaroenlapnopparat, Leandro Sierra, Pojsakorn Danpanichkul, Panisara Fangsaard, Phuuwadith Wattanachayakul, Apichat Kaewdech |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Livers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-4389/4/4/46 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes
by: Ankita Dua, et al.
Published: (2025-08-01) -
Metabolite perturbations in type 1 diabetes associated with metabolic dysfunction-associated steatotic liver disease
by: Adeyinka Taiwo, et al.
Published: (2025-06-01) -
Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis
by: Like Zhou, et al.
Published: (2025-01-01) -
The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
by: Donghee Kim, et al.
Published: (2025-04-01) -
Clinical Phenotypes May be Able to Identify Populations With Nonalcoholic Fatty Liver-Spectrum Disease
by: Bridget M. Geyer, et al.
Published: (2025-01-01)